Results 1 to 10 of about 7,679 (193)

A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database

Frontiers in Pharmacology, 2023
Mepolizumab is primarily used in the treatment of asthma, eosinophilic granulomatosis with polyangiitis, eosinophilia syndrome, and chronic rhinitis with nasal polyps.
Zou Fan, Cui Zhiwei, Lou Siyu
exaly   +3 more sources

Improved long-term prognosis of eosinophilic granulomatosis with polyangiitis: retrospective analysis of 87 patients after biologic therapy introduction in Japan [PDF]

Scientific Reports
Five-year survival in eosinophilic granulomatosis with polyangiitis (EGPA) exceeds 90%, but long-term prognosis is poor. We examined prognosis in 87 Japanese EGPA patients, seen between April 2018 and December 2024, after mepolizumab introduction ...
Yuga Yamashita, Nami Masumoto, Sachiko Takaoka, Takuya Nakashima, Kaho Matsunaga, Yuka Kodama, Kosuke Terada, Hinako Masumitsu, Atsushi Miyasaka, Tatsuya Muraoka, Takeshi Kaneko, Naomi Tsurikisawa   +11 more
doaj   +2 more sources

Effectiveness of low-dose mepolizumab in refractory eosinophilic granulomatosis with polyangiitis: systemic steroid use and remission [PDF]

The Korean Journal of Internal Medicine
Background/Aims This study investigated the clinical efficacy of low-dose mepolizumab (100 mg) in controlling severe eosinophilic asthma, aiming to induce eosinophilic granulomatosis with polyangiitis (EGPA) remission and reduce systemic steroid usage ...
Mi-Ae Kim, Ji-Hyun Lee, Eun-Kyung Kim, Jung-Hyun Kim, Jisoo Park, Se Hee Lee, Tae-Bum Kim   +6 more
doaj   +2 more sources

Real-world impact of mepolizumab on pediatric and adolescent patients with severe asthma [PDF]

Journal of Allergy and Clinical Immunology: Global
Background: Real-world evidence on the effectiveness of mepolizumab in children and adolescents with severe asthma (SA) is limited. Objective: We sought to evaluate mepolizumab’s impact on the clinical and health care resource utilization (HCRU) burden ...
Michelle L. Hernandez, MD, Tom Corbridge, MD, François Laliberté, MA, Malena Mahendran, MSc, Annalise Hilts, BA, Kaixin Zhang, MSc, Arijita Deb, PhD   +6 more
doaj   +2 more sources

A real-world disproportionality analysis of mepolizumab based on the FDA adverse event reporting system

Frontiers in Pharmacology, 2023
Background: Mepolizumab has been approved by the FDA for add-on maintenance treatment of severe asthma with an eosinophilic phenotype. Real-world studies on mepolizumab-associated adverse events are limited. The present study aimed to explore mepolizumab-
Huqun Li, Chongshu Wang, Aiping Deng, Cuilian Guo   +3 more
doaj   +1 more source

Mepolizumab [PDF]

Hospital Pharmacy, 2016
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing ...
Cada, Dennis J, Bindler, Ross J, Baker, Danial E   +2 more
openaire   +3 more sources

Severe asthma remaining well‐controlled after mepolizumab discontinuation: A case report and literature review

Respirology Case Reports, 2023
Mepolizumab, a humanized anti‐IL‐5 monoclonal antibody used for severe asthma, results in a reduced rate of asthma exacerbation, improved lung function, reduced oral corticosteroid use, and improved quality of life.
Takahiro Matsuyama, Yuya Tomioka, Hiromi Matsuyama, Yusuke Kamenohara, Kengo Tanigawa, Yoichi Dotake, Yoko Hagihara, Koichi Takagi, Kentaro Machida, Hiromasa Inoue   +9 more
doaj   +1 more source

Long-term mepolizumab treatment reduces relapse rates in super-responders with eosinophilic granulomatosis with polyangiitis

Allergy, Asthma & Clinical Immunology, 2023
Background The mainstay of treatment for eosinophilic granulomatosis with polyangiitis (EGPA) is systemic corticosteroid therapy; some patients also receive intravenous immunoglobulins, other immunosuppressive agents, and biologics.
Nami Masumoto, Chiyako Oshikata, Ryo Nakadegawa, Yuto Motobayashi, Reeko Osada, Saki Manabe, Takeshi Kaneko, Naomi Tsurikisawa   +7 more
doaj   +1 more source

Potential impact of mepolizumab in stepping down anti-osteporotic treatment in corticosteroid-dependent asthma

Frontiers in Pharmacology, 2023
Oral corticosteroids (OCS) are commonly used for the acute management of severe asthma exacerbations or as maintenance therapy; however, chronic use is associated with significant toxicities, e.g., osteoporosis. In the REal worlD Effectiveness and Safety
Christian Domingo, Christian Domingo, Ana Sogo, Ana Sogo, Enrique Casado, Eva Martínez-Moragón, Marina Blanco-Aparicio, Teresa Carrillo, Teresa Carrillo, David Bañas-Conejero, María-Guadalupe Sánchez-Herrero   +10 more
doaj   +1 more source

Real-Life Performance of Mepolizumab in T2-High Severe Refractory Asthma with the Overlapping Eosinophilic-Allergic Phenotype

Biomedicines, 2022
Severe asthma (SA) is categorized into multiple overlapping phenotypes and clinical characteristics driven by complex mechanistic inflammatory pathways. Mepolizumab is a human monoclonal antibody effectively targeting interleukin-5 in severe eosinophilic
Ruperto González-Pérez, Paloma Poza-Guedes, Elena Mederos-Luis, Inmaculada Sánchez-Machín   +3 more
doaj   +1 more source